Evidence map›Paper›PMID 40401969›Full record

ArticleMicrobiology spectrum2025

Identification of West Nile virus infection by anti-premembrane antibodies in Nicaraguan children prior to 2007-2009.

Wen-Yang Tsai, Alanna C Tseng, Guan-Hua Chen, Szu-Chia Hsieh, Angel Balmaseda, Vivek R Nerurkar, Eva Harris, Wei-Kung Wang

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wen-Yang Tsai *Department of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii at Manoa, Honolulu, Hawaii, USA.ORCID 0000-0002-3407-8223
Alanna C Tseng *Department of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii at Manoa, Honolulu, Hawaii, USA.ORCID 0000-0001-7246-5032
Guan-Hua ChenDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Szu-Chia HsiehDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Angel BalmasedaNational Virology Laboratory, National Center for Diagnosis and Reference, Ministry of Health, Managua, Nicaragua.
Vivek R NerurkarDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii at Manoa, Honolulu, Hawaii, USA.ORCID 0000-0002-2044-2784
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, USA.ORCID 0000-0002-7238-4037
Wei-Kung WangDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii at Manoa, Honolulu, Hawaii, USA.ORCID 0000-0002-6670-4663

Funding

Project 3 - Ex vivo immune profiling of dengue viruses and vaccinesU19AI118610 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FERNANDEZ-SESMA, ANA, HARRIS, EVA · 2015 to 2021
$46.6M
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Daniela Weiskopf · 2015 to 2026
$34.1M
Small Grants ProgramP30GM114737 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI NERURKAR, VIVEK RAMCHANDRA · 2015 to 2022
$8.1M
Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease riskU01AI153416 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI HARRIS, EVA · 2021 to 2025
$4.9M
Epidemiological, Clinical & Immunological Studies of Zika, dengue and chikungunyaR01AI099631 · NIAID · SUSTAINABLE SCIENCES INSTITUTE · PI BALMASEDA, ANGEL LAZARO · 2012 to 2021
$1.8M
Mature virus-like particles as a new strategy for dengue virus vaccinesR01AI110769 · NIAID · UNIVERSITY OF HAWAII AT MANOA · PI WANG, WEI-KUNG · 2014 to 2018
$1.5M
Long-term safety and effectiveness of Dengvaxia in the PhilippinesR01AI186073 · NIAID · UNIVERSITY OF HAWAII AT MANOA · PI Wei-Kung Wang · 2024 to 2026
$1.5M
Multiplex Serodiagnostic Assays for Pathogenic Arboviruses in BrazilR01AI149502 · NIAID · UNIVERSITY OF HAWAII AT MANOA · PI WANG, WEI-KUNG · 2020 to 2023
$624k
Bill and Melinda Gates Foundation (GF) VE-1National Institute of Allergy and Infectious Diseases P01AI106695, U01AI153416, U19AI118610National Institute of Allergy and Infectious Diseases R01AI099631National Institute of Allergy and Infectious Diseases R01AI110769, R01AI149502NIAID NIH HHS P01 AI106695NIAID NIH HHS R01 AI099631NIAID NIH HHS R01 AI110769NIAID NIH HHS R01 AI149502NIAID NIH HHS R01 AI186073NIAID NIH HHS U01 AI153416NIAID NIH HHS U19 AI118610NIGMS NIH HHS P30 GM114737NIGMS NIH HHS P30GM114737
6 · The paper itself

Abstract

Since its introduction to the Western Hemisphere in 1999 in New York City, West Nile virus (WNV) has spread throughout the continental USA and moved into Canada, Mexico, Caribbean, and Central and South Americas. While WNV has caused ~7 million human infections and >59,000 cases in the USA and >6,000 cases in Canada, only few human cases have been reported in Latin America. Due to the cross-reactivity of anti-envelope antibodies, the detection of WNV infection by serology to explore its epidemiology in Latin America, where multiple flaviviruses co-circulate, remains a challenge. Previously, we reported that anti-premembrane (prM) antibodies can distinguish between four flavivirus (WNV, dengue, Zika, and yellow fever viruses) infections. In this study, we examined 73 samples from 40 Zika cases from a pediatric cohort in Nicaragua using Western blot analysis and detected anti-prM antibodies to WNV in three participants in samples collected between 2016 and 2017, suggesting previous WNV infection prior to ZIKV infection. Analysis of available archived samples revealed anti-WNV prM antibodies in the earliest samples (2007-2009), which were further confirmed by plaque reduction neutralization test, suggesting that they were infected by WNV prior to 2007-2009. Our report of WNV infection in three Nicaraguan children, corresponding to a seropositive rate of 7.5%, highlights the transmission of WNV in humans in Central America prior to 2007. Future studies with improved serological tests for WNV surveillance in Latin America are needed to enhance our understanding of the epidemiology and transmission of WNV in the Western Hemisphere. IMPORTANCE: Since its arrival to North America in 1999, West Nile virus (WNV) has caused multiple outbreaks in birds and humans, with thousands of human cases in the USA and Canada, whereas in Latin America, WNV has mainly been detected in birds and horses with few human cases. Due to cross-reactivity of anti-envelope antibodies among different flaviviruses, detection of WNV infection by serology to explore its epidemiology in Latin America remains a challenge. Previously, we reported that anti-premembrane antibodies can discriminate four flavivirus infections using Western blot analysis. Based on anti-WNV premembrane antibodies and confirmation by neutralization test, we report three Nicaraguan children with WNV infection, corresponding to a seropositive rate of 7.5%. Our findings underscore the transmission of WNV in humans in Central America and the application of improved seroepidemiological tools to address the knowledge gaps on the prevalence and distribution of WNV in Latin America and the Western Hemisphere.

Indexed as

Antibodies, ViralViral Envelope ProteinsWest Nile FeverWest Nile virusChildChild, PreschoolFemaleHumansInfantMaleNicaraguaZika VirusZika Virus InfectionAntibodies, ViralViral Envelope ProteinsantibodyNicaraguapremembraneserological testWest Nile virus

Identifiers

PMID40401969
PMCPMC12210876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.